User:Cguajardo92/sandbox

Life Length is a Spanish biotechnology research and application company located in Madrid, Spain. The company was founded in 2010 by Stephen J. Matlin to study life expectancy using proprietary telometric analysis technology (TAT) for measuring telomere length. The technology used is based on HT Q-FISH (High Throughput Quantitative Fluorescence in site Hybridization) which was originally developed in the laboratory of scientist Maria Blasco, current Director of the National Center for Oncology Research in Spain (CNIO).

Overview
Life Length was founded on September 28, 2010 as a spin-off of the CNIO with the aim of commercializing Telomere Analysis Technology (TAT). The co-founders are Stephen J. Matlin, current CEO of Life Length, and Dr. Maria Blasco, Director of the CNIO.

Additional proprietary technologies developed include Q-TRAP, Telomapping, Terminal Repeat Fragmentation, and Quality-PCR.

Projects
In September of 2016, Life Length received 3.1 million euros from the Horizon 2020 program, which will allow the development of the ONCOCHECK project, a series of clinical studies that will involve more than 1,200 adults and 300 children suffering from one of multiple existing types of cancer, including breast, prostate, lung and leukemia, among others.

This project would operate in conjunction with a network of hospitals such as the University Hospital of October 12th, University Hospital Puerta de Hierro, University Hospital Niño Jesus, Vall d'hebron Hospital, and the Clara Campal Comprehensive Cancer Center.

Other projects and studies conducted include: